Time to Ambulation After ProGlide Closure
Recruiting now · Not applicable
Conditions studied: Femoral Access Site Closure, Ambulation, Vascular Access Complication, Vascular Access Site Management
In brief
Transradial access has become the standard for coronary procedures due to fewer vascular complications and shorter bed rest, yet transfemoral access remains essential for complex peripheral interventions requiring larger sheaths and stronger support. Vascular closure devices (VCDs), particularly suture-mediated devices such as ProGlide, have improved femoral access by reducing hemostasis time, ambulation delay, and patient discomfort. Although early ambulation after ProGlide closure has been reported, current practice varies widely, and the relationship between ambulation timing and vascular complications remains unclear. This trial aims to evaluate the effect of different ambulation times after ProGlide closure in transfemoral peripheral angiography or intervention, with the goal of identifying the optimal time to ambulation that balances safety and efficiency.
Key facts
- Study ID
- NCT07179536
- Run by
- Chinese Academy of Medical Sciences, Fuwai Hospital
- People needed
- 300
- Starts
- 2025-10-01
- Expected to finish
- 2026-03-30
- Last updated by the study team
- 2026-01-23
Who can join
Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Scheduled for peripheral angiography or endovascular intervention via transfemoral access.
- Femoral artery puncture site located at the common femoral artery.
- Use of 6-8F vascular sheath.
- Hemostasis achieved with 6F ProGlide closure device (defined as no active bleeding, no hematoma formation, and no ischemia of the punctured limb after closure).
- Preoperative ankle-brachial index (ABI) > 0.9 on both sides.
- Conscious, cooperative, and with normal lower limb mobility.
You may not qualify if…
- Undergoing carotid artery intervention.
- Femoral artery diameter < 5 mm, or effective lumen < 5 mm due to plaque burden.
- History of vascular complications at the puncture site.
- Abnormal cardiopulmonary function.
- Intraoperative platelet count < 80 × 10⁹/L, or use of thrombolytic agents.
- Cognitive impairment, uncooperative, or limited lower limb mobility.
Where it is running
- Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College — Beijing, Beijing Municipality, China (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.